CGEM · Cullinan Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $42.12M | - | $41.97M | $61.03M | $41.46M | - | $35.51M | $36.26M | $30.65M | - |
| SG&A | $11.57M | - | $13.63M | $14.77M | $13.54M | - | $13.35M | $13.77M | $12.34M | - |
| Total Operating Expenses | $53.70M | - | $55.59M | $75.80M | $55.00M | - | $48.85M | $50.03M | $42.99M | - |
| D&A | $79.0K | - | - | - | $76.0K | - | - | - | $76.0K | - |
| Operating Income | ($53.70M) | - | ($55.59M) | ($75.80M) | ($55.00M) | - | ($48.85M) | ($50.03M) | ($42.99M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($49.66M) | - | ($50.61M) | ($70.06M) | ($48.50M) | - | ($40.56M) | ($42.03M) | ($37.15M) | - |
| EPS - Basic | - | - | - | - | - | - | ($0.69) | ($0.75) | ($0.86) | - |
| EPS - Diluted | - | - | - | - | - | - | ($0.69) | ($0.75) | ($0.86) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75.08M | $88.33M | $103.33M | $72.82M | $76.66M | $83.00M | $102.08M | $115.02M | $74.23M | $98.43M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.51M | $841.0K | $1.72M | $2.46M | $3.40M | $1.68M | $2.12M | $1.55M | $3.71M | $2.49M |
| Current Assets | $361.41M | $386.76M | $342.24M | $275.91M | $317.77M | $414.67M | $592.04M | $677.80M | $445.72M | $480.19M |
| Total Assets | $402.98M | $448.37M | $484.13M | $520.33M | $579.68M | $621.82M | $653.25M | $681.22M | $449.43M | $484.18M |
| Current Liabilities | $35.15M | $37.74M | $32.76M | $28.06M | $27.35M | $30.65M | $24.20M | $23.48M | $21.93M | $28.14M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $36.81M | $39.64M | $32.76M | $28.18M | $27.84M | $31.50M | $25.39M | $25.00M | $23.77M | $30.29M |
| Stockholders' Equity | $366.17M | $408.73M | $451.37M | $492.15M | $551.84M | $590.33M | $627.86M | $656.22M | $425.67M | $453.70M |
| Retained Earnings | ($637.78M) | ($588.12M) | ($537.41M) | ($486.80M) | ($416.74M) | ($368.24M) | ($320.59M) | ($280.03M) | ($238.00M) | ($200.86M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($46.05M) | - | - | - | ($43.16M) | - | - | - | ($38.25M) | - |
| Investing Cash Flow | $32.41M | - | - | - | $36.80M | - | - | - | $12.96M | - |
| Financing Cash Flow | $380.0K | - | - | - | $0 | - | - | - | $1.08M | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($38.25M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.03 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.3% | - | -10.5% | -13.5% | -8.4% | - | -6.2% | -6.2% | -8.3% | - |
| Return on equity | -13.6% | - | -11.2% | -14.2% | -8.8% | - | -6.5% | -6.4% | -8.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.28 | 10.25 | 10.45 | 9.83 | 11.62 | 13.53 | 24.46 | 28.87 | 20.33 | 17.07 |
| Quick ratio | 10.28 | 10.25 | 10.45 | 9.83 | 11.62 | 13.53 | 24.46 | 28.87 | 20.33 | 17.07 |
| Cash ratio | 2.14 | 2.34 | 3.15 | 2.60 | 2.80 | 2.71 | 4.22 | 4.90 | 3.39 | 3.50 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.10 | 1.10 | 1.07 | 1.06 | 1.05 | 1.05 | 1.04 | 1.04 | 1.06 | 1.07 |
| Liabilities / Assets | 0.09 | 0.09 | 0.07 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.05 | 0.06 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | 1.6x | 1.5x | 1.7x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 2.4% | - | -13.8% | -51.5% | -27.9% | - | -8.0% | -33.0% | 31.5% | - |
| Net income growth (YoY) | -2.4% | - | -24.8% | -66.7% | -30.6% | - | -3.5% | -30.5% | 35.9% | - |
| EPS growth (YoY) | - | - | - | - | - | - | 24.2% | 8.5% | -218.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 25.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -33.6% | -30.8% | -28.1% | -25.0% | 29.6% | 30.1% | 33.9% | 31.4% | -12.4% | -15.2% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Cullinan Oncology against the 5 most active filers in the same SIC group.